Pharmacokinetics and Biodistribution of Thymoquinone-loaded Nanostructured Lipid Carrier After Oral and Intravenous Administration into Rats

Fatin Hannani Zakarial Ansar,1 Saiful Yazan Latifah,1,2 Wan Hamirul Bahrin Wan Kamal,3 Khei Choong Khong,3 Yen Ng,3 Jia Ning Foong,1 Banulata Gopalsamy,2 Wei Keat Ng,1 Chee Wun How,4 Yong Sze Ong,1 Rasedee Abdullah,2,5 Mohd Yusmaidie Aziz6 1Laboratory of Molecular Medicine, Institute of Bioscience,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zakarial Ansar FH, Latifah SY, Wan Kamal WHB, Khong KC, Ng Y, Foong JN, Gopalsamy B, Ng WK, How CW, Ong YS, Abdullah R, Aziz MY
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	thymoquinone nanostructured lipid carrier bioavailability biodistribution pharmacokinetics. Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/327aeeb06b794737b56d05a68793be6c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:327aeeb06b794737b56d05a68793be6c
record_format	dspace
spelling	oai:doaj.org-article:327aeeb06b794737b56d05a68793be6c2021-12-02T11:18:24ZPharmacokinetics and Biodistribution of Thymoquinone-loaded Nanostructured Lipid Carrier After Oral and Intravenous Administration into Rats1178-2013https://doaj.org/article/327aeeb06b794737b56d05a68793be6c2020-10-01T00:00:00Zhttps://www.dovepress.com/pharmacokinetics-and-biodistribution-of-thymoquinone-loaded-nanostruct-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Fatin Hannani Zakarial Ansar,1 Saiful Yazan Latifah,1,2 Wan Hamirul Bahrin Wan Kamal,3 Khei Choong Khong,3 Yen Ng,3 Jia Ning Foong,1 Banulata Gopalsamy,2 Wei Keat Ng,1 Chee Wun How,4 Yong Sze Ong,1 Rasedee Abdullah,2,5 Mohd Yusmaidie Aziz6 1Laboratory of Molecular Medicine, Institute of Bioscience, Universiti Putra Malaysia, Serdang, Selangor, Malaysia; 2Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, Malaysia; 3Laboratory of Preclinical Study, Block 24, Medical Technology Division, Malaysian Nuclear Agency, Kajang, Selangor, Malaysia; 4Laboratory of Vaccines and Immunotherapeutics, Institute of Bioscience, Universiti Putra Malaysia, Serdang, Selangor, Malaysia; 5Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, Universiti Putra Malaysia, Serdang, Selangor, Malaysia; 6Advanced Medical and Dental Institute, University of Science Malaysia, Kepala Batas, Pulau Pinang, MalaysiaCorrespondence: Saiful Yazan Latifah; Wan Hamirul Bahrin Wan Kamal Tel +60 3 89472308Fax +60 3 89436178Email latifahsy@upm.edu.my; mirul@nuclearmalaysia.gov.myBackground: Thymoquinone (TQ), an active compound isolated from Nigella sativa, has been proven to exhibit various biological properties such as antioxidant. Although oral delivery of TQ is valuable, it is limited by poor oral bioavailability and low solubility. Recently, TQ-loaded nanostructured lipid carrier (TQ-NLC) was formulated with the aim of overcoming the limitations. TQ-NLC was successfully synthesized by the high-pressure homogenization method with remarkable physiochemical properties whereby the particle size is less than 100 nm, improved encapsulation efficiency and is stable up to 24 months of storage. Nevertheless, the pharmacokinetics and biodistribution of TQ-NLC have not been studied. This study determined the bioavailability of oral and intravenous administration of thymoquinone-loaded nanostructured lipid carrier (TQ-NLC) in rats and its distribution to organs.Materials and Methods: TQ-NLC was radiolabeled with technetium-99m before the administration to the rats. The biodistribution and pharmacokinetics parameters were then evaluated at various time points. The rats were imaged at time intervals and the percentage of the injected dose/gram (%ID/g) in blood and each organ was analyzed.Results: Oral administration of TQ-NLC exhibited greater relative bioavailability compared to intravenous administration. It is postulated that the movement of TQ-NLC through the intestinal lymphatic system bypasses the first metabolism and therefore enhances the relative bioavailability. However, oral administration has a slower absorption rate compared to intravenous administration where the AUC0-∞ was 4.539 times lower than the latter.Conclusion: TQ-NLC had better absorption when administered intravenously compared to oral administration. However, oral administration showed greater bioavailability compared to the intravenous route. This study provides the pharmacokinetics and biodistribution profile of TQ-NLC in vivo which is useful to assist researchers in clinical use.Keywords: thymoquinone, nanostructured lipid carrier, bioavailability, biodistribution, pharmacokineticsZakarial Ansar FHLatifah SYWan Kamal WHBKhong KCNg YFoong JNGopalsamy BNg WKHow CWOng YSAbdullah RAziz MYDove Medical Pressarticlethymoquinonenanostructured lipid carrierbioavailabilitybiodistributionpharmacokinetics.Medicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 15, Pp 7703-7717 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	thymoquinone nanostructured lipid carrier bioavailability biodistribution pharmacokinetics. Medicine (General) R5-920
spellingShingle	thymoquinone nanostructured lipid carrier bioavailability biodistribution pharmacokinetics. Medicine (General) R5-920 Zakarial Ansar FH Latifah SY Wan Kamal WHB Khong KC Ng Y Foong JN Gopalsamy B Ng WK How CW Ong YS Abdullah R Aziz MY Pharmacokinetics and Biodistribution of Thymoquinone-loaded Nanostructured Lipid Carrier After Oral and Intravenous Administration into Rats
description	Fatin Hannani Zakarial Ansar,1 Saiful Yazan Latifah,1,2 Wan Hamirul Bahrin Wan Kamal,3 Khei Choong Khong,3 Yen Ng,3 Jia Ning Foong,1 Banulata Gopalsamy,2 Wei Keat Ng,1 Chee Wun How,4 Yong Sze Ong,1 Rasedee Abdullah,2,5 Mohd Yusmaidie Aziz6 1Laboratory of Molecular Medicine, Institute of Bioscience, Universiti Putra Malaysia, Serdang, Selangor, Malaysia; 2Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, Malaysia; 3Laboratory of Preclinical Study, Block 24, Medical Technology Division, Malaysian Nuclear Agency, Kajang, Selangor, Malaysia; 4Laboratory of Vaccines and Immunotherapeutics, Institute of Bioscience, Universiti Putra Malaysia, Serdang, Selangor, Malaysia; 5Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, Universiti Putra Malaysia, Serdang, Selangor, Malaysia; 6Advanced Medical and Dental Institute, University of Science Malaysia, Kepala Batas, Pulau Pinang, MalaysiaCorrespondence: Saiful Yazan Latifah; Wan Hamirul Bahrin Wan Kamal Tel +60 3 89472308Fax +60 3 89436178Email latifahsy@upm.edu.my; mirul@nuclearmalaysia.gov.myBackground: Thymoquinone (TQ), an active compound isolated from Nigella sativa, has been proven to exhibit various biological properties such as antioxidant. Although oral delivery of TQ is valuable, it is limited by poor oral bioavailability and low solubility. Recently, TQ-loaded nanostructured lipid carrier (TQ-NLC) was formulated with the aim of overcoming the limitations. TQ-NLC was successfully synthesized by the high-pressure homogenization method with remarkable physiochemical properties whereby the particle size is less than 100 nm, improved encapsulation efficiency and is stable up to 24 months of storage. Nevertheless, the pharmacokinetics and biodistribution of TQ-NLC have not been studied. This study determined the bioavailability of oral and intravenous administration of thymoquinone-loaded nanostructured lipid carrier (TQ-NLC) in rats and its distribution to organs.Materials and Methods: TQ-NLC was radiolabeled with technetium-99m before the administration to the rats. The biodistribution and pharmacokinetics parameters were then evaluated at various time points. The rats were imaged at time intervals and the percentage of the injected dose/gram (%ID/g) in blood and each organ was analyzed.Results: Oral administration of TQ-NLC exhibited greater relative bioavailability compared to intravenous administration. It is postulated that the movement of TQ-NLC through the intestinal lymphatic system bypasses the first metabolism and therefore enhances the relative bioavailability. However, oral administration has a slower absorption rate compared to intravenous administration where the AUC0-∞ was 4.539 times lower than the latter.Conclusion: TQ-NLC had better absorption when administered intravenously compared to oral administration. However, oral administration showed greater bioavailability compared to the intravenous route. This study provides the pharmacokinetics and biodistribution profile of TQ-NLC in vivo which is useful to assist researchers in clinical use.Keywords: thymoquinone, nanostructured lipid carrier, bioavailability, biodistribution, pharmacokinetics
format	article
author	Zakarial Ansar FH Latifah SY Wan Kamal WHB Khong KC Ng Y Foong JN Gopalsamy B Ng WK How CW Ong YS Abdullah R Aziz MY
author_facet	Zakarial Ansar FH Latifah SY Wan Kamal WHB Khong KC Ng Y Foong JN Gopalsamy B Ng WK How CW Ong YS Abdullah R Aziz MY
author_sort	Zakarial Ansar FH
title	Pharmacokinetics and Biodistribution of Thymoquinone-loaded Nanostructured Lipid Carrier After Oral and Intravenous Administration into Rats
title_short	Pharmacokinetics and Biodistribution of Thymoquinone-loaded Nanostructured Lipid Carrier After Oral and Intravenous Administration into Rats
title_full	Pharmacokinetics and Biodistribution of Thymoquinone-loaded Nanostructured Lipid Carrier After Oral and Intravenous Administration into Rats
title_fullStr	Pharmacokinetics and Biodistribution of Thymoquinone-loaded Nanostructured Lipid Carrier After Oral and Intravenous Administration into Rats
title_full_unstemmed	Pharmacokinetics and Biodistribution of Thymoquinone-loaded Nanostructured Lipid Carrier After Oral and Intravenous Administration into Rats
title_sort	pharmacokinetics and biodistribution of thymoquinone-loaded nanostructured lipid carrier after oral and intravenous administration into rats
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/327aeeb06b794737b56d05a68793be6c
work_keys_str_mv	AT zakarialansarfh pharmacokineticsandbiodistributionofthymoquinoneloadednanostructuredlipidcarrierafteroralandintravenousadministrationintorats AT latifahsy pharmacokineticsandbiodistributionofthymoquinoneloadednanostructuredlipidcarrierafteroralandintravenousadministrationintorats AT wankamalwhb pharmacokineticsandbiodistributionofthymoquinoneloadednanostructuredlipidcarrierafteroralandintravenousadministrationintorats AT khongkc pharmacokineticsandbiodistributionofthymoquinoneloadednanostructuredlipidcarrierafteroralandintravenousadministrationintorats AT ngy pharmacokineticsandbiodistributionofthymoquinoneloadednanostructuredlipidcarrierafteroralandintravenousadministrationintorats AT foongjn pharmacokineticsandbiodistributionofthymoquinoneloadednanostructuredlipidcarrierafteroralandintravenousadministrationintorats AT gopalsamyb pharmacokineticsandbiodistributionofthymoquinoneloadednanostructuredlipidcarrierafteroralandintravenousadministrationintorats AT ngwk pharmacokineticsandbiodistributionofthymoquinoneloadednanostructuredlipidcarrierafteroralandintravenousadministrationintorats AT howcw pharmacokineticsandbiodistributionofthymoquinoneloadednanostructuredlipidcarrierafteroralandintravenousadministrationintorats AT ongys pharmacokineticsandbiodistributionofthymoquinoneloadednanostructuredlipidcarrierafteroralandintravenousadministrationintorats AT abdullahr pharmacokineticsandbiodistributionofthymoquinoneloadednanostructuredlipidcarrierafteroralandintravenousadministrationintorats AT azizmy pharmacokineticsandbiodistributionofthymoquinoneloadednanostructuredlipidcarrierafteroralandintravenousadministrationintorats
_version_	1718396042324475904

Pharmacokinetics and Biodistribution of Thymoquinone-loaded Nanostructured Lipid Carrier After Oral and Intravenous Administration into Rats

Ejemplares similares